- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07946614
Heparin Versus Saline Locking of Peripheral Venous Catheters (HESAL)
Heparin Versus Saline Locking of Peripheral Venous Catheters: a Multicenter Retrospective Cohort Study
The goal of this observational study is to learn whether locking peripheral venous catheters with heparin keeps them open (patent) better than locking them with saline, in adults admitted to hospital who have a peripheral venous catheter for intermittent treatment. The main questions it aims to answer are:
- Is the percentage of blocked peripheral venous catheters higher in patients whose catheters are locked with saline than in those whose catheters are locked with heparin?
- Do the rates of other catheter-related complications (phlebitis, catheter-related bloodstream infection, extravasation, and leakage at the insertion site) differ between the two groups?
- Which clinical and drug-related factors are associated with catheter blockage?
Researchers will compare patients admitted to a hospital that routinely locks catheters with saline with patients admitted to a hospital that routinely locks catheters with heparin.
연구 개요
상태
상세 설명
Maintaining the patency of peripheral venous catheters (PVCs) used intermittently is a relevant and unresolved clinical question. Reference care bundles such as Bacteremia Zero and Phlebitis Zero do not explicitly address whether catheters should be locked with saline or heparin, and the evidence comparing both options, especially taking into account the interval between infusions, is limited.
The two hospitals of the Consorci Sanitari de l'Alt Penedès i Garraf offer a natural experiment: Hospital Residència Sant Camil systematically locks PVCs with sodium heparin 20 IU/mL , while Hospital Comarcal de l'Alt Penedès locks them with sterile 0.9% saline. Allocation to each cohort is determined solely by the hospital of admission. Data for the year before the start of the study will be extracted retrospectively from the electronic medical record, where nurses record the status of the catheter and the reason for removal or replacement on each shift.
The primary analysis will compare, with a superiority approach, the percentage of blocked catheters between cohorts, considering only the first catheter inserted in each patient. Logistic regression will adjust for confounders that are unbalanced between cohorts or clinically relevant (age, sex, type and schedule of intravenous medication, anticoagulation, and coagulation disorders). Sensitivity analyses will include all catheters per patient (mixed models or generalized estimating equations) and will exclude patients at particularly high risk of blockage. Assuming an absolute difference of 3% between cohorts, alpha 5%, power 80%, and 5% losses, 1,725 patients per cohort (3,450 in total) are needed. Data analysts will be blinded to the cohort during the primary analysis.
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Noemí Casaponsa
- 전화번호: 43197 0034938960025
- 이메일: recerca@csapg.cat
연구 장소
-
-
Barcelona
-
Sant Pere de Ribes, Barcelona, 스페인, 08810
- Hospital Residència Sant Camil
-
연락하다:
- Noemí Casaponsa
- 전화번호: 43197 0034938960025
- 이메일: recerca@csapg.cat
-
수석 연구원:
- Esther Moreno Rubio
-
Vilafranca del Penedès, Barcelona, 스페인, 08720
- Hospital Comarcal de l'Alt Penedès
-
연락하다:
- Noemí Casaponsa
- 전화번호: 43197 0034938960025
- 이메일: recerca@csapg.cat
-
수석 연구원:
- Esther Moreno Rubio
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
All adults admitted to Hospital Residència Sant Camil or Hospital Comarcal de l'Alt Penedès (both hospital belonging to CSAPG) during the study period who had at least one peripheral venous catheter inserted for intermittent treatment.
설명
Inclusion Criteria:
- Admitted to Hospital Residència Sant Camil (CSAPG) or Hospital Comarcal de l'Alt Penedès (CSAPG) during the study period
- At least one peripheral venous catheter for intermittent treatment, not inserted in a medical emergency
- Aged 18 years or older
Exclusion Criteria:
- Known allergy to heparin
- Treatment with systemic unfractionated sodium heparin
- Dialysis
- Venous catheter used only for diagnostic tests
- Venous catheter used only for transfusion of blood products
- Participation in another clinical study with drugs or procedures that may affect catheter patency
- Severe heparin-induced thrombocytopenia in recent months
- Uncontrolled active bleeding during admission
- Cerebral aneurysm or dissecting aortic aneurysm, except in association with corrective surgery
- Confirmed or suspected cerebrovascular hemorrhage
- Severe uncontrolled hypertension
- Severe coagulation disorders: platelets below 30,000/µL, prothrombin time ratio above 1.7, or activated partial thromboplastin time ratio above 1.7
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: RETROSPECTIVE
코호트 및 개입
그룹/코호트 |
|---|
|
Cohort A: saline locking
|
|
Cohort B: heparin locking
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of blocked peripheral venous catheters
기간: Hospital discharge, up to 12 weeks
|
Percentage of patients whose first peripheral venous catheter was removed or replaced because of blockage (occlusion). |
Hospital discharge, up to 12 weeks
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- CSAPG-98
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
IPD (without personal identification data) could be shared by requirement from other researchers after the end of the study, and only for research purposes and previous approval of promotor center of the study (CSAPG). Anyway, Spanish and European Union legal policy about data protection will strictly be followed (IPD will not be transferred outside European Union).
IPD 공유 기간
After publication of main results of the study.
IPD 공유 액세스 기준
IPD will be shared only for scientific research purposes and following the Spanish and European Union normative law about data protection. The requirements will be directed to the IP of the study. The IP will evaluate the request to verify and evaluate the data that is requested and the purposes for which it is requested. Next, the IP will transfer the request to the promotor center the study for the final decision.
IPD 공유 지원 정보 유형
- 연구_프로토콜
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .